Synthesis, proapoptotic screening, and structure–activity relationships of novel aza-lupane triterpenoids
作者:Aye Aye Mar、Erika L. Szotek、Ali Koohang、William P. Flavin、David A. Eiznhamer、Michael T. Flavin、Ze-Qi Xu
DOI:10.1016/j.bmcl.2010.07.120
日期:2010.9
Apoptosis is a highly regulated process by which excessive cells are eliminated in order to maintain normal cell development and tissue homeostasis. Resistance to apoptosis often contributes to failure in cancer prevention and treatment. Apoptotic cell death regulators are considered important targets for discovery and development of new therapeutic agents in oncology research. A class of novel aza-lupane triterpenoids were designed, synthesized, and evaluated for antitumor activity against a panel of cancer cell lines of different histogenic origin and for ability to induce apoptosis. 3,30-Bis(aza) derivatives were identified not only to possess improved cytotoxicity compared to the natural product betulinic acid but also to affect cell death predominantly via apoptosis, whereas the mono(aza) derivatives apparently triggered cell death via different, non-apoptotic pathway(s). (c) 2010 Elsevier Ltd. All rights reserved.
Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
申请人:Xu Ze-Qi
公开号:US20070232577A1
公开(公告)日:2007-10-04
The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit cancer and treat, prevent, or inhibit the foregoing diseases.